Cite

    Jadon, D. et al. (n.d.). 248 Sustained improvements in disease activity for up to two-years with ixekizumab in patients with active psoriatic arthritis who were either biologic-naïve or with previous inadequate response to tumour necrosis factor inhibitor therapy. Rheumatology. p. . [Online].